New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies

American Journal of Health-System Pharmacy

Volumn 69, Issue 12, 2012, Pages 1031-1037

  Li, Edward ^a   Trovato, James A ^b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PALIFERMIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ACUTE HEMORRHAGIC PANCREATITIS; AMYLASE BLOOD LEVEL; APHTHOUS STOMATITIS; APHTHOUS ULCER; BREAST CANCER; BREAST METASTASIS; CANCER RADIOTHERAPY; CONVULSION; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DYSGEUSIA; DYSPHAGIA; FEBRILE NEUTROPENIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MOUTH HYGIENE; MUCOSA INFLAMMATION; NAUSEA; ORAL MUCOSITIS; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; STOMATITIS; VOMITING;

EID: 84862834545     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100531     Document Type: Review

References (36)

1. Elting LS, Cooksley C, Chambers M et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003; 98:1531-9. (Pubitemid 37151510)
2. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol. 2010; 21(suppl 5):v261-5.
3. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100(suppl 9):2026-46. (Pubitemid 38525884)
4. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109:820-31. (Pubitemid 46335677)
5. Bensinger W, Schubert M, Ang KK et al. NCCN task force report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008; 6(suppl 1):S1-21.
6. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009; 27:127-45.
7. Harris DJ, Eilers J, Harriman A et al. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008; 12:141-52.
8. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008; 359:1143-54.
9. Le QT, Kim HE, Schneider CJ et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011; 29:2808-14.
10. Henke M, Alfonsi M, Foa P et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2011; 29:2815-20.
11. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351:2590-8. (Pubitemid 39628580)
12. Nonzee NJ, Dandade NA, Patel U et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008; 113:1446-52.
13. Centers for Medicare and Medicaid Services. Medicare Part B drug average sales price. www.cms.gov/mcrpartbdrugavgsalesprice/ (accessed 2011 Jul 26).
14. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353:2477-90. (Pubitemid 41770167)
15. Hudes GR, Carducci MA, Choueiri TK et al. NCCN task force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw. 2011; 9(suppl 1):S1-29.
16. Afinitor (everolimus) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
17. Nexavar (sorafenib) prescribing information. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.; 2011.
18. Sutent (sunitinib) prescribing information. New York: Pfizer Inc.; 2011.
19. Torisel (temsirolimus) prescribing information. Philadelphia: Wyeth Pharmaceuticals Inc.; 2011.
20. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009; 45:1015-20.
21. Sonis S, Treister N, Chawla S et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010; 116:210-5.
22. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011; 47:1287-98.
23. Campistol JM, de Fijter JW, Flechner SM et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010; 24:149-56.
24. Messadi DV, Younai F. Aphthous ulcers. Dermatol Ther. 2010; 23:281-90.
25. Tykerb (lapatinib) prescribing information. Research Triangle Park, NC: Glaxo- SmithKline; 2011.
26. Tarceva (erlotinib) prescribing information. South San Francisco, CA: Genentech USA, Inc.; 2011.
27. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-43. (Pubitemid 46021510)
28. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008; 26:5544-52.
29. Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in HER2- positive breast cancer. Curr Oncol Rep. 2008; 10:10-7.
30. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007; 25:1960-6. (Pubitemid 46972777)
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med. 2005; 353:123-32. (Pubitemid 41058344)
32. Hutson TE, Figlin RA, Kuhn JG et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008; 13:1084-96.
33. Bellmunt J, Szczylik C, Feingold J et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008; 19:1387-92.
34. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47:441-8.
35. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008; 53:917-30.
36. Rosen LS, Abdi E, Davis ID et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006; 24:5194-200. (Pubitemid 46631362)